With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
ASIA
New Manufacturing Platform at Hsinchu Operational
GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech’s Research Centre and manufacturing plant in Hsinchu, Taiwan. The new GMP compliant manufacturing platform is similar to that of the production process at JHL Biotech’s KUBio modular biopharmaceutical factory currently under construction by GE Healthcare at the Biolake Science Park in Wuhan, China.
JHL Biotech’s FlexFactory in Taiwan will be used for cell line development, process development, and cGMP manufacturing in pre-clinical and early-stage clinical work. In addition, it will serve as a proving ground for JHL Biotech for technology transfer. GE Healthcare’s experienced Shanghai Fast Trak team will validate equipment at the site and will train local JHL Biotech staff.
Olivier Loeillot, General Manager affordable to more people by utilising innovations such as FlexFactory. Our biomanufacturing capability increases with the installation
of cGMP manufacturing in our Taiwan facility. Because our biomanufacturing capabilities are shared across our facilities in Asia, we give our partners a unique offering.”
Racho Jordanov, Co-founder, President and CEO of JHL Biotech, added, “JHL Biotech will make world-class biopharmaceuticals of Enterprise Solutions, GE Healthcare Life Sciences, commented, “Our offering of tools, technologies and services for biomanufacturing has strength in both breadth and depth. For JHL Biotech we have been able to take an approach which recognises the differing requirements of multiple sites, whilst at the same time allowing them to replicate processes. FlexFactory is highly complementary to our KUBio offering, primarily aimed at those organisations repurposing or expanding an existing site.”
28502pr@reply-direct.com by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Sustained Market Sets Stage for Growth
A partnership between The Vision Care business group of ZEISS and Optik Tunggal has been extended with an Advanced Technology clause in addition to pre-signed agreements on manufacturing, distribution and licencing. The partnership enables Optik Tunggal to produce world class lenses for the Indonesian market.
“The sustained upward trend in the Indonesian market has convinced us to put our relationship with Optik Tunggal on a new footing, and to set the course for further growth under the umbrella of Zeiss technology,” said Ven Raman, Managing Director of Zeiss Southeast Asia.
“It is marriage of the brands. On one hand Optik Tunggal has a history of 80 years; on the other, Zeiss has been an optical leader in the world for more than 165 years. We are keen to learn from ZEISS and incorporate the best technology to provide quality lenses and services to spectacle-wearers of Indonesia,” said Michael W. Kurniawan, Director of Optik Tunggal.
Scientists Seek Alternative to Iridium for Storage Devices An international team of European and Japanese scientists led
by the University of York has launched a 4.6m collaborative project funded by the European Commission (EC) and the Japanese Science and Technology Agency (JST) to develop new materials to replace the scarce metal Iridium commonly used in magnetic storage devices.
Under the EU-backed project, the research team, which includes Bielefeld and Konstanz Universities, Germany, Budapest University of Technology and Economics, Hungary, and UK-based Mackintosh Consultants, as well as the University of York’s Departments of Electronics and Physics, intends to develop Heusler alloy fi lms to provide a cost-effective alternative to Iridium. The European scientists will be working closely with a Japanese research team led by Professor Koki Takanashi from Tohoku University.
Project Scientifi c Co-ordinator Dr Atsufumi Hirohata, from the University of York’s Department of Electronics, said: “It is widely recognised that spin electronic technologies will displace volatile semiconductor memory technology within the next decade. Therefore the lack of availability of one crucial
element from within the periodic table is a critical issue to be solved urgently. The price of Iridium has risen by a factor of 4 in the last fi ve years and by more than a factor of 10 in the last decade. It is expected to soar perhaps by a factor of 100 due to its wider application.”
Professor Takanashi said: “My colleagues at the High Energy Accelerator Research Tsukuba and my staff here at Tohoku University are excited to be working with such prestigious universities in Europe on this challenging but vital research. Iridium is such a rare metal, twice as rare as gold in the earth’s crust, that relying on it for such a key future technology represents a very high risk strategy.
Our research programme will impact this key material directly by providing an improved understanding of a wide ranging class of ternary alloys, and we will seek to fi nd new materials and new compositions of Heusler Alloys to replace the need for Iridium in spin electronic devices.”
28505pr@reply-direct.com XEI Appoint VCT as Distributors in Taiwan
XEI Scientifi c Inc, maker of plasma leaning systems for electron microscopes and other vacuum chambers, has appointed the V-TEK Company, VTC, as distribution partners for their decontamination products in Taiwan. Founded in 1989 as a specialist dealer for the IC semiconductor, Optoelectronic and Solar PV industries in Taiwa, VTC supply customers with systems, tools, raw materials, chemicals and complementary services.
VTC CEO and Founder Albert Hong was very positive about this new partnership. “XEI is the technology leader with their Evactron De-Contaminator systems. The products are a natural fi t to our current portfolio and we are confi dent we will be able to help XEI to grow in this market. This is based on our tri-win approach for customers, suppliers and itself through our capability, performance, loyalty and friendship the motto and culture of VTC.
VTC’s partners, customers and suppliers, are always impressed by the passion that we have when it comes to sales and service
activities. VTC has won its reputation and friendship in related industries and suppliers in the world for more than 20 years.
Moreover, VTC’s commitment and spirit is a value-added maker as anywhere, anytime partner’s, customers and manufacturers, reputation, business and friendship are the one that we/VTC count most.”
Speaking about this new agreement, XEI Vice President of Sales & Marketing, Daniel R Kleinen said “VTC provides us with an extremely experienced and well-qualifi ed partner for the exciting, high-growth markets of Taiwan. XEI has now sold more than 1750 Evactron systems worldwide solving contamination problems in many different environments using instrumentation such as electron microscopes, FIBs and other vacuum sample chambers.
28504pr@reply-direct.com
Michael W. Kurniawan and Ven Raman inked the memorandum of understanding for “Advanced Technology Collaboration” on 22nd January 2014 in Jakarta, Indonesia, in the presence of Dr. Michael Kaschke, President and CEO of Carl Zeiss AG.
28506pr@reply-direct.com Medical University to use
X-MAN Cell Lines in Japan Horizon Discovery™ a leading provider of research tools to support translational genomics and the development of personalised medicines, has entered into a limited use academic license agreement with a Japanese medical university covering 250 of Horizon’s X-MAN™ genetically defi ned, isogenic cell lines.
Kam Dhaliwal, VP Sales, Horizon Discovery, commented: “This is a very signifi cant deal for Horizon Discovery, covering a large number of cell lines and representing a large investment by the university. We are delighted that our distribution partnership in Japan with Summit Pharmaceuticals International (SPI) is proving so productive. Summit has proven to be extremely effective in opening the Japanese market for Horizon and we anticipate further adoption of our products and services in Japan in the future.”
The Director of the Translational Research Centre at the university commented: “Horizon’s X-MAN cell lines offer a unique and valuable resource for the study of specifi c, disease- related mutations. We are look forward to applying the X-MAN technology in our research projects.”
28503pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market- leading journal International Labmate.
Email:
info@intlabmate.com
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
